TrialPath
Recruiting

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

NCT07492927 · Xijing Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Eligibility criteria
Inclusion Criteria: 1. Blood prostate-specific antigen PSA\>4ng/dl; 2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging. 3. The patient is willing to undergo prostate biopsy. Exclusion Criteria: 1. Previous diagnosis of prostate cancer through prostate biopsy; 2. History of other malignant tumors in the past two years; 3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Study design
Enrollment target: 1700 participants
Age groups: adult, older_adult
Timeline
Starts: 2021-03-12
Estimated completion: 2027-06-30
Last updated: 2026-03-25
Primary outcomes
  • The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing csPCa (The time of prostate biopsy)
Sponsor
Xijing Hospital · other
With: Shaanxi Provincial People's Hospital, Weinan Central Hospital, Shaanxi University of Chinese Medicine, LanZhou University, Qinghai University, Ningxia Medical University, Northwestern University, Yan'an University Affiliated Hospital, Air Force Military Medical University, China
Contacts & investigators
ContactJianhua Jiao, MD. · contact · 1531769428@qq.com · +86 029 84771062
InvestigatorWeijun Qin, MD. · study_chair, Xijing Hospital
All locations (10)
Northwestern Memorial HospitalRecruiting
Chicago, Illinois, United States
The First Hospital of Lanzhou UniversityRecruiting
Lanzhou, Gansu, China
General Hospital of Ningxia Medical UniversityRecruiting
Yinchuan, Ningxia, China
Qinghai University Affiliated HospitalRecruiting
Xining, Qinghai, China
Weinan Central HospitalRecruiting
Weinan, Shaanxi, China
Shaanxi Provincial People's HospitalRecruiting
Xi'an, Shaanxi, China
Xijing 986 HospitalRecruiting
Xi'an, Shaanxi, China
The Second Affiliated Hospital of Shaanxi University of Chinese MedicineRecruiting
Xianyang, Shaanxi, China
Yan'an University Affiliated HospitalRecruiting
Yan’an, Shaanxi, China
Xijing HospitalRecruiting
Xi'an, China
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer · TrialPath